Investigational Drug Information for MB-102
✉ Email this page to a colleague
What is the development status for investigational drug MB-102?
MB-102 is an investigational drug.
There have been 5 clinical trials for MB-102.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2023.
The most common disease conditions in clinical trials are Renal Insufficiency, Kidney Diseases, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are MediBeacon, Mustang Bio, and [disabled in preview].
Summary for MB-102
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 30 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2023-03-01) |
| Vendors | 3 |
Recent Clinical Trials for MB-102
| Title | Sponsor | Phase |
|---|---|---|
| Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring | MediBeacon | Phase 3 |
| Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects | MediBeacon | Phase 3 |
| Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. | Mustang Bio | Phase 1/Phase 2 |
Clinical Trial Summary for MB-102
Top disease conditions for MB-102
Top clinical trial sponsors for MB-102
US Patents for MB-102
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
